Boehringer Ingelheim Venture Fund
  • Home
  • Exited Investments

Our Exited Investments


Okairos AG is a clinical stage vaccine company. Its technology platform is based on genetic vaccines delivered by replication-incompetent adenovirus vectors. Such vaccines induce a strong T-cell immune response which has the potential to prevent or treat a range of diseases that currently escape the immune system, such as mutating infectious diseases and cancer. Company has entered clinical stage with programs for malaria and hepatitis C. Okairos is a Swiss based company with laboratories in Italy. Okairos was acquired in May 2013 by GSK.
Year of investment: 2010; BIVF Board Representative: Knut Elbers